New hope for rare blood cancer: lenalidomide dose study completed

NCT ID NCT02302469

First seen Jan 07, 2026 · Last updated May 16, 2026 · Updated 18 times

Summary

This study looked at the drug lenalidomide in 17 people with Waldenstrom macroglobulinemia, a rare blood cancer that had returned or stopped responding to other treatments. The main goal was to find a dose that is safe and tolerable. Researchers measured side effects and how many patients responded to the drug. The approach is about controlling the disease, not curing it.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for WALDENSTROM MACROGLOBULINEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • CH LENS

    Lens, 62307, France

  • Centre Hospitalier Lyon Sud

    Pierre-Bénite, 69495, France

  • Centre Hospitalier de la côte basque

    Bayonne, 64109, France

  • Ch Clermond Ferrand

    Clermont-Ferrand, 63000, France

  • Ch Nantes

    Nantes, 44 093, France

  • Chru Lille

    Lille, 59037, France

  • Groupe hospitalier Pitié Salpétrière

    Paris, 75651, France

Conditions

Explore the condition pages connected to this study.